点击此处阅读调查报告全文
Our fourth annual report on Hong Kong-listed biotech companies examines how the sector performed during the continuing challenging market conditions of the last full calendar year. Although the number of...more
点击此处阅读调查报告全文
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more
4/25/2023
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Corporate Governance ,
Foreign Corporations ,
Healthcare ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Life Sciences ,
Listing Rules ,
Popular ,
Publicly-Traded Companies
Our second annual report on Hong Kong-listed biotech companies demonstrates the continued health of the sector. The report provides a comprehensive overview of the market in its current state, examining key data points for...more
This update provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In particular,...more
7/14/2020
/ Acquisitions ,
Amended Rules ,
Biotechnology ,
Board of Directors ,
Censures ,
Corporate Executives ,
Enforcement Actions ,
False Statements ,
Hang Seng China Enterprises Index (HSCEI) ,
Hang Seng Index (HSI) ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Internal Controls ,
Listing Applications ,
Listing Rules ,
Medical Devices ,
Medical Research ,
Mergers ,
Misappropriation ,
Misleading Statements ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Sanctions ,
Secondary Listings ,
SFC ,
Shareholders ,
Takeovers ,
Weighted Voting Rights (WVR)
This update provides an overview of recent developments that will affect preparation of annual results and annual reports for companies listed on The Stock Exchange of Hong Kong Limited (HKEX).
In particular, it covers...more
1/6/2020
/ Annual Reports ,
Biotechnology ,
Capital Requirements ,
Committee Meetings ,
Corporate Governance ,
Disclosure Requirements ,
Dual Class Share Structures ,
EBITDA ,
Enforcement Actions ,
Environmental Social & Governance (ESG) ,
Financial Statements ,
Foreign Corporations ,
Foreign Issuers ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Investment Funds ,
Listing Rules ,
Materiality ,
Non-GAAP Financial Measures ,
Publicly-Traded Companies ,
Secondary Listings ,
Shareholder Meetings ,
Trade Suspensions ,
Voting Rights